NOVOZYMES A/S/S (OTCMKTS:NVZMY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports. The brokerage presently has a $55.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 8.06% from the stock’s previous close.

According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “

Other analysts also recently issued research reports about the company. Goldman Sachs Group downgraded NOVOZYMES A/S/S from a “buy” rating to a “sell” rating in a research note on Wednesday, April 1st. ValuEngine raised NOVOZYMES A/S/S from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, BNP Paribas downgraded NOVOZYMES A/S/S from an “outperform” rating to a “neutral” rating in a research note on Tuesday, January 14th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. NOVOZYMES A/S/S currently has a consensus rating of “Hold” and an average target price of $55.00.

Shares of NVZMY opened at $50.90 on Friday. The business’s 50 day moving average is $45.87 and its 200 day moving average is $48.14. The company has a market capitalization of $15.05 billion, a PE ratio of 31.47, a price-to-earnings-growth ratio of 22.46 and a beta of 0.70. NOVOZYMES A/S/S has a 12-month low of $37.99 and a 12-month high of $55.51. The company has a current ratio of 1.29, a quick ratio of 0.76 and a debt-to-equity ratio of 0.23.

NOVOZYMES A/S/S (OTCMKTS:NVZMY) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.42. The company had revenue of $558.75 million for the quarter. NOVOZYMES A/S/S had a return on equity of 26.90% and a net margin of 21.08%. Equities research analysts predict that NOVOZYMES A/S/S will post 1.65 earnings per share for the current year.

About NOVOZYMES A/S/S

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.

Featured Article: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on NOVOZYMES A/S/S (NVZMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NOVOZYMES A/S/S (OTCMKTS:NVZMY)

Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.